Skip to main content
Top
Published in: Pharmaceutical Medicine 3/2020

Open Access 01-06-2020 | Leading Article

Establishing Patient Registries for Rare Diseases: Rationale and Challenges

Authors: Vanessa Boulanger, Marissa Schlemmer, Suzanne Rossov, Allison Seebald, Pamela Gavin

Published in: Pharmaceutical Medicine | Issue 3/2020

Login to get access

Abstract

Globally, an estimated 350 million people are affected by a rare disease diagnosis. Knowledge limitations persist for the majority of rare conditions due to systemic and structural challenges in healthcare and research. Disease-specific patient populations are often small and geographically dispersed; funding support for research is restricted; and diagnostic delays are common due to disease complexities, limited medical training for practitioners, and evolving foundational knowledge related to disease characterization. Patient registries can be effective, convenient, and cost-efficient tools to support documentation of the natural history of a disease, centering patients as research partners in the process while uniting rare communities around a common initiative. Current global trends towards innovative and patient-centered healthcare are enabling patient registries to increasingly emerge as valuable tools for use within rare disease research and drug development. This article describes the value of and rationale for establishing rare disease patient registries and the considerations and challenges that stakeholders, such as researchers, industry, health care providers, and patient community organizations, may encounter.
Literature
1.
go back to reference Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Lipkin G, Calvert M. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13(1):61.CrossRef Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Lipkin G, Calvert M. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13(1):61.CrossRef
2.
go back to reference Groft SC. Rare diseases research: expanding collaborative translational research opportunities. Chest. 2013;144(1):16–23.CrossRef Groft SC. Rare diseases research: expanding collaborative translational research opportunities. Chest. 2013;144(1):16–23.CrossRef
4.
go back to reference Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, Hughes DA, International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest Groups. Rare disease terminology and definitions—a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18:906–14.CrossRef Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, Hughes DA, International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest Groups. Rare disease terminology and definitions—a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18:906–14.CrossRef
5.
go back to reference Kaufmann P, Pariser AR, Austin C. From scientific discovery to treatments for rare diseases—the view from the National Center for Advancing Translational Sciences—Office of Rare Diseases Research. Orphanet J Rare Dis. 2018;13(1):196.CrossRef Kaufmann P, Pariser AR, Austin C. From scientific discovery to treatments for rare diseases—the view from the National Center for Advancing Translational Sciences—Office of Rare Diseases Research. Orphanet J Rare Dis. 2018;13(1):196.CrossRef
6.
go back to reference Gavin P. The importance of natural histories for rare diseases. Expert Opinion Orphan Drugs. 2015;3:355–7.CrossRef Gavin P. The importance of natural histories for rare diseases. Expert Opinion Orphan Drugs. 2015;3:355–7.CrossRef
7.
go back to reference Kodra Y, de la Paz MP, Coi A, Santoro M, Bianchi F, Ahmed F, Rubinstein YR, Weinbach J, Taruscio D. Data quality in rare diseases registries. Adv Exp Med Biol. 2017;1031:149–64.CrossRef Kodra Y, de la Paz MP, Coi A, Santoro M, Bianchi F, Ahmed F, Rubinstein YR, Weinbach J, Taruscio D. Data quality in rare diseases registries. Adv Exp Med Biol. 2017;1031:149–64.CrossRef
8.
go back to reference Maccarthy J, Guerin S, Wilson AG, Dorris ER. Facilitating public and patient involvement in basic and preclinical health research. PLoS One. 2019;14(5):e0216600.CrossRef Maccarthy J, Guerin S, Wilson AG, Dorris ER. Facilitating public and patient involvement in basic and preclinical health research. PLoS One. 2019;14(5):e0216600.CrossRef
9.
go back to reference Fink AK, Loeffler DR, Marshall BC, Gross CH, Morgan WJ. Data that empower: the success and promise of CF patient registries. Pediatr Pulm. 2017;52:544–51.CrossRef Fink AK, Loeffler DR, Marshall BC, Gross CH, Morgan WJ. Data that empower: the success and promise of CF patient registries. Pediatr Pulm. 2017;52:544–51.CrossRef
12.
go back to reference Martins AM, Obikawa SK. The importance of patient registries for rare diseases. Expert Opinion Orphan Drugs. 2013;1:769–72.CrossRef Martins AM, Obikawa SK. The importance of patient registries for rare diseases. Expert Opinion Orphan Drugs. 2013;1:769–72.CrossRef
13.
go back to reference D’Agnolo HM, Kievit W, Andrade RJ, Karlsen TH, Wedemeyer H, Drenth JP. Creating an effective clinical registry for rare diseases. United Eur Gastroenterol J. 2016;4(3):333–8.CrossRef D’Agnolo HM, Kievit W, Andrade RJ, Karlsen TH, Wedemeyer H, Drenth JP. Creating an effective clinical registry for rare diseases. United Eur Gastroenterol J. 2016;4(3):333–8.CrossRef
14.
go back to reference Tabor HK, Goldenberg A. What precision medicine can learn from rare genetic disease research and translation. AMA J Ethics. 2018;20(9):834–40.CrossRef Tabor HK, Goldenberg A. What precision medicine can learn from rare genetic disease research and translation. AMA J Ethics. 2018;20(9):834–40.CrossRef
20.
go back to reference Wise J, de Barron AG, Splendiani A, Balali-Mood B, Vasant D, Little E, Mellino G, Harrow I, Smith I, Taubert J, van Bochove K, Romacker M, Walgemoed P, Jimenez RC, Winnenburg R, Plasterer T, Gupta V, Hedley V. Implementation and relevance of FAIR data principles in biopharmaceutical R&D. Drug Discov Today. 2019;24(4):933–8.CrossRef Wise J, de Barron AG, Splendiani A, Balali-Mood B, Vasant D, Little E, Mellino G, Harrow I, Smith I, Taubert J, van Bochove K, Romacker M, Walgemoed P, Jimenez RC, Winnenburg R, Plasterer T, Gupta V, Hedley V. Implementation and relevance of FAIR data principles in biopharmaceutical R&D. Drug Discov Today. 2019;24(4):933–8.CrossRef
24.
go back to reference Chawla NV, Davis DA. Bringing big data to personalized healthcare: a patient-centered framework. J Gen Intern Med. 2013;28(3):660–5.CrossRef Chawla NV, Davis DA. Bringing big data to personalized healthcare: a patient-centered framework. J Gen Intern Med. 2013;28(3):660–5.CrossRef
25.
go back to reference O’Connor AM, Llewellyn-Thomas HA, Flood AB. Modifying unwarranted variations in health care: shared decision making using patient decision aids. Health Aff (Millwood). 2004;Suppl Variation:63–72.CrossRef O’Connor AM, Llewellyn-Thomas HA, Flood AB. Modifying unwarranted variations in health care: shared decision making using patient decision aids. Health Aff (Millwood). 2004;Suppl Variation:63–72.CrossRef
26.
go back to reference Ieva F, Gale CP, Sharples LD. Contemporary roles of registries in clinical cardiology: when do we need randomized trials? Expert Rev Cardiovasc Ther. 2014;12(12):1383–6.CrossRef Ieva F, Gale CP, Sharples LD. Contemporary roles of registries in clinical cardiology: when do we need randomized trials? Expert Rev Cardiovasc Ther. 2014;12(12):1383–6.CrossRef
30.
go back to reference Flood J, Minkler M, Hennessey LS, Estrada J, Falbe J. The collective impact model and its potential for health promotion: overview and case study of a healthy retail initiative in San Francisco. Health Educ Behav. 2015;42(5):654–68.CrossRef Flood J, Minkler M, Hennessey LS, Estrada J, Falbe J. The collective impact model and its potential for health promotion: overview and case study of a healthy retail initiative in San Francisco. Health Educ Behav. 2015;42(5):654–68.CrossRef
32.
go back to reference Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, Nguyen T, Paulus K, Merkel PA. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009;96(1):20–6.CrossRef Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, Nguyen T, Paulus K, Merkel PA. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009;96(1):20–6.CrossRef
33.
37.
go back to reference Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013;28(9):1142–50.CrossRef Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013;28(9):1142–50.CrossRef
38.
go back to reference Pannucci CJ, Wilkins EG. Identifying and avoiding bias in research. Plast Reconstr Surg. 2010;126(2):619–25.CrossRef Pannucci CJ, Wilkins EG. Identifying and avoiding bias in research. Plast Reconstr Surg. 2010;126(2):619–25.CrossRef
Metadata
Title
Establishing Patient Registries for Rare Diseases: Rationale and Challenges
Authors
Vanessa Boulanger
Marissa Schlemmer
Suzanne Rossov
Allison Seebald
Pamela Gavin
Publication date
01-06-2020
Publisher
Springer International Publishing
Published in
Pharmaceutical Medicine / Issue 3/2020
Print ISSN: 1178-2595
Electronic ISSN: 1179-1993
DOI
https://doi.org/10.1007/s40290-020-00332-1

Other articles of this Issue 3/2020

Pharmaceutical Medicine 3/2020 Go to the issue

Update

Forum